Effect of resveratrol on Treg/Th17 signaling and ulcerative colitis treatment in mice

World Journal of Gastroenterology

Volumn 21, Issue 21, 2015, Pages 6572-6581

  Yao, Jun ^a   Wei, Cheng ^a   Wang, Jian Yao ^b   Zhang, Ru ^a   Li, Ying Xue ^a   Wang, Li Sheng ^a  

^a JINAN UNIVERSITY   (China)

^b SHENZHEN CHILDREN'S HOSPITAL   (China)

Author keywords

Hypoxia inducible factor ; Mammalian target of rapamycin; Resveratrol; Th17 cells; Treg cells; Ulcerative colitis

Indexed keywords

DEXTRAN SULFATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; RESVERATROL; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; AUTACOID; CYTOKINE; HIF1A PROTEIN, MOUSE; MTOR PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE; STILBENE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH17 CELL; THERAPY EFFECT; TISSUE LEVEL; ULCERATIVE COLITIS; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; COLITIS; COLON; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SPLEEN; TIME FACTOR;

ANIMALS; COLITIS; COLON; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INFLAMMATION MEDIATORS; MALE; MICE, INBRED BALB C; SIGNAL TRANSDUCTION; SPLEEN; STAT3 TRANSCRIPTION FACTOR; STILBENES; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; TIME FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84930790032     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i21.6572     Document Type: Article

References (43)

1. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 1620-1633 [PMID: 15168372 DOI: 10.1053/j.gastro.2004.03.024]
2. Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010; 16: 338-346 [PMID: 19637362 DOI: 10.1002/ibd.20997]
3. Yao J, Wang JY, Lai MG, Li YX, Zhu HM, Shi RY, Mo J, Xun AY, Jia CH, Feng JL, Wang LS, Zeng WS, Liu L. Treatment of mice with dextran sulfate sodium-induced colitis with human interleukin 10 secreted by transformed Bifidobacterium longum. Mol Pharm 2011; 8: 488-497 [PMID: 21271712 DOI: 10.1021/mp100331r]
4. Eastaff-Leung N, Mabarrack N, Barbour A, Cummins A, Barry S. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol 2010; 30: 80-89 [PMID: 19936899 DOI: 10.1007/s10875-009-9345-1]
5. Raza A, Yousaf W, Giannella R, Shata MT. Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease. Expert Rev Clin Immunol 2012; 8: 161-168 [PMID: 22288454 DOI: 10.1586/eci.11.96]
6. Fuss IJ. Is the Th1/Th2 paradigm of immune regulation applicable to IBD? Inflamm Bowel Dis 2008; 14 Suppl 2: S110-S112 [PMID: 18816734 DOI: 10.1002/ibd.20683]
7. Liu ZJ, Yadav PK, Su JL, Wang JS, Fei K. Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol 2009; 15: 5784-5788 [PMID: 19998498 DOI: 10.3748/wjg.15.5784]
8. Ogino H, Nakamura K, Ihara E, Akiho H, Takayanagi R. CD4+CD25+ regulatory T cells suppress Th17-responses in an experimental colitis model. Dig Dis Sci 2011; 56: 376-386 [PMID: 20521112 DOI: 10.1007/s10620-010-1286-2]
9. Abraham C, Cho J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 1090-1100 [PMID: 19253307 DOI: 10.1002/ibd.20894]
10. Nutsch K, Hsieh C. When T cells run out of breath: the HIF-1αstory. Cell 2011; 146: 673-674 [PMID: 21884928 DOI: 10.1016/j.cell.2011.08.018]
11. Awasthi A, Murugaiyan G, Kuchroo VK. Interplay between effector Th17 and regulatory T cells. J Clin Immunol 2008; 28: 660-670 [PMID: 18810613 DOI: 10.1007/s10875-008-9239-7]
12. Kleczynska W, Jakiela B, Plutecka H, Milewski M, Sanak M, Musial J. Imbalance between Th17 and regulatory T-cells in systemic lupus erythematosus. Folia Histochem Cytobiol 2011; 49: 646-653 [PMID: 22252759]
13. Nistala K, Wedderburn LR. Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. Rheumatology (Oxford) 2009; 48: 602-606 [PMID: 19269955 DOI: 10.1093/rheumatology/kep028]
14. Yao J, Wang JY, Liu L, Li YX, Xun AY, Zeng WS, Jia CH, Wei XX, Feng JL, Zhao L, Wang LS. Anti-oxidant effects of resveratrol on mice with DSS-induced ulcerative colitis. Arch Med Res 2010; 41: 288-294 [PMID: 20637373 DOI: 10.1016/j.arcmed.2010.05.002]
15. Trapp V, Parmakhtiar B, Papazian V, Willmott L, Fruehauf JP. Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Angiogenesis 2010; 13: 305-315 [PMID: 20927579 DOI: 10.1007/s10456-010-9187-8]
16. Singh UP, Singh NP, Singh B, Hofseth LJ, Taub DD, Price RL, Nagarkatti M, Nagarkatti PS. Role of resveratrol-induced CD11b(+) Gr-1(+) myeloid derived suppressor cells (MDSCs) in the reduction of CXCR3(+) T cells and amelioration of chronic colitis in IL-10(-/-) mice. Brain Behav Immun 2012; 26: 72-82 [PMID: 21807089 DOI: 10.1016/j.bbi.2011.07.236]
17. Abdallah DM, Ismael NR. Resveratrol abrogates adhesion molecules and protects against TNBS-induced ulcerative colitis in rats. Can J Physiol Pharmacol 2011; 89: 811-818 [PMID: 22029500 DOI: 10.1139/Y11-080]
18. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000; 118: S68-S82 [PMID: 10868899 DOI: 10.1016/ S0016-5085(00)70007-2]
19. Katz JA. Advances in the medical therapy of inflammatory bowel disease. Curr Opin Gastroenterol 2002; 18: 435-440 [PMID: 17033318]
20. Aberra FN, Lichtenstein GR. Infliximab in ulcerative colitis. Gastroenterol Clin North Am 2006; 35: 821-836 [PMID: 17129815 DOI: 10.2147/BTT.S2249]
21. Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, Bala M, Johanns J, Olson A, Hanauer SB. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007; 102: 794-802 [PMID: 17324131 DOI: 10.1111/j.1572-0241.2007.01094.x]
22. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008; 58: 1197-1200 [PMID: 18383395 DOI: 10.1002/art.23373]
23. Ardizzone S, Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs 2005; 65: 2253-2286 [PMID: 16266194 DOI: 10.1053/gast.2002.33426]
24. Reddy JG, Loftus EV. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am 2006; 35: 837-855 [PMID: 17129816 DOI: 10.1016/ j.gtc.2006.09.008]
25. Elmali N, Baysal O, Harma A, Esenkaya I, Mizrak B. Effects of resveratrol in inflammatory arthritis. Inflammation 2007; 30: 1-6 [PMID: 17115116 DOI: 10.1007/s10753-006-9012-0]
26. Ma ZH, Ma QY, Wang LC, Sha HC, Wu SL, Zhang M. Effect of resveratrol on peritoneal macrophages in rats with severe acute pancreatitis. Inflamm Res 2005; 54: 522-527 [PMID: 16389574 DOI: 10.1007/s00011-005-1388-z]
27. Sun L, Nava GM, Stappenbeck TS. Host genetic susceptibility, dysbiosis, and viral triggers in inflammatory bowel disease. Curr Opin Gastroenterol 2011; 27: 321-327 [PMID: 21483258 DOI: 10.1097/MOG.0b013e32834661b4]
28. Wang Y, Zhao Y. Influence of Zuoguiyin on Antioxidation in Blood Thymus And Spleen Index of Senile Mice. Zhongguo Shiyan Fangjixue Zazhi 2007; 13: 67-68
29. Hirata I, Yasumoto S, Toshina K, Inoue T, Nishikawa T, Murano N, Murano M, Wang FY, Katsu K. Evaluation of the effect of pyrrolidine dithiocarbamate in suppressing inflammation in mice with dextran sodium sulfate-induced colitis. World J Gastroenterol 2007; 13: 1666-1671 [PMID: 17461468]
30. Scharl M, Rogler G. Inflammatory bowel disease pathogenesis: what is new? Curr Opin Gastroenterol 2012; 28: 301-309 [PMID: 22573190 DOI: 10.1097/MOG.0b013e328353e61e]
31. Stephani J, Radulovic K, Niess JH. Gut microbiota, probiotics and inflammatory bowel disease. Arch Immunol Ther Exp (Warsz) 2011; 59: 161-177 [PMID: 21445715 DOI: 10.1007/s00005-011-0122-5]
32. Hundorfean G, Neurath MF, Mudter J. Functional relevance of T helper 17 (Th17) cells and the IL-17 cytokine family in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 180-186 [PMID: 21381156 DOI: 10.1002/ibd.21677]
33. Ko JK, Auyeung KK. Inflammatory bowel disease: etiology, pathogenesis and current therapy. Curr Pharm Des 2014; 20: 1082-1096 [PMID: 23782147 DOI: 10.1016/S0016-5085(98)70381-6]
34. Szkaradkiewicz A, Marciniak R, Chudzicka-Strugała I, Wasilewska A, Drews M, Majewski P, Karpiński T, Zwoździak B. Proinflammatory cytokines and IL-10 in inflammatory boweldisease and colorectal cancer patients. Arch Immunol Ther Exp (Warsz) 2009; 57: 291-294 [PMID: 19578817 DOI: 10.1007/s00005-009-0031-z]
35. Lohr J, Knoechel B, Caretto D, Abbas AK. Balance of Th1 and Th17 effector and peripheral regulatory T cells. Microbes Infect 2009; 11: 589-593 [PMID: 19376259 DOI: 10.1016/j.micinf.2009.04.012]
36. Gupta S. Immune homeostasis: regulatory T cells (Treg) and molecules. J Clin Immunol 2008; 28: 617-618 [PMID: 18982430 DOI: 10.1007/s10875-008-9259-3]
37. Unutmaz D, Pulendran B. The gut feeling of Treg cells: IL-10 is the silver lining during colitis. Nat Immunol 2009; 10: 1141-1143 [PMID: 19841645 DOI: 10.1038/ni1109-1141]
38. Tseng WP, Yang SN, Lai CH, Tang CH. Hypoxia induces BMP-2 expression via ILK, Akt, mTOR, and HIF-1 pathways in osteoblasts. J Cell Physiol 2010; 223: 810-818 [PMID: 20232298 DOI: 10.1002/jcp.22104]
39. Mitsuyama K, Matsumoto S, Masuda J, Yamasakii H, Kuwaki K, Takedatsu H, Sata M. Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease. Anticancer Res 2007; 27: 3749-3756 [PMID: 17970038 DOI: 10.1002/ibd.20342]
40. Carey R, Jurickova I, Ballard E, Bonkowski E, Han X, Xu H, Denson LA. Activation of an IL-6: STAT3-dependent transcriptome in pediatric-onset inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 446-457 [PMID: 18069684]
41. Jung JE, Kim HS, Lee CS, Shin YJ, Kim YN, Kang GH, Kim TY, Juhnn YS, Kim SJ, Park JW, Ye SK, Chung MH. STAT3 inhibits the degradation of HIF-1alpha by pVHL-mediated ubiquitination. Exp Mol Med 2008; 40: 479-485 [PMID: 18985005 DOI: 10.3858/emm.2008.40.5.479]
42. Martín AR, Villegas I, Sánchez-Hidalgo M, de la Lastra CA. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol 2006; 147: 873-885 [PMID: 16474422 DOI: 10.1038/sj.bjp.0706469]
43. Mahal HS, Mukherjee T. Scavenging of reactive oxygen radicals by resveratrol: antioxidant effect. Res Chem Intermediat 2006; 32: 59-71 [DOI: 10.1163/156856706775012941]